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Abstract
Planar cell polarity (PCP) pathways control the orientation and alignment of epithelial cells within tissues. Van
Gogh-like 2 (Vangl2) is a key PCP protein that is required for the normal differentiation of kidney glomeruli
and tubules. Vangl2 has also been implicated in modifying the course of acquired glomerular disease, and here,
we further explored how Vangl2 impacts on glomerular pathobiology in this context. Targeted genetic deletion
of Vangl2 in mouse glomerular epithelial podocytes enhanced the severity of not only irreversible accelerated
nephrotoxic nephritis but also lipopolysaccharide-induced reversible glomerular damage. In each proteinuric model,
genetic deletion of Vangl2 in podocytes was associated with an increased ratio of active-MMP9 to inactive MMP9,
an enzyme involved in tissue remodelling. In addition, by interrogating microarray data from two cohorts of
renal patients, we report increased VANGL2 transcript levels in the glomeruli of individuals with focal segmental
glomerulosclerosis, suggesting that the molecule may also be involved in certain human glomerular diseases. These
observations support the conclusion that Vangl2 modulates glomerular injury, at least in part by acting as a brake
on MMP9, a potentially harmful endogenous enzyme.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Van Gogh-like 2 (Vangl2) regulates planar cell polar-
ity (PCP), controlling orientation and alignment of
epithelial cells within tissues [1]. PCP is implicated in
heart [2], lung [3], neural tube [4,5] and blood vessel
[6] development. In kidneys, Vangl2 is expressed in
epithelial podocytes in forming glomeruli, the blood
ultrafiltration units, and in nephron and collecting
duct tubules [7,8]. Homozygous Loop-tail mice with
Vangl2Lp point mutations have malformed kidneys with
a paucity of collecting ducts and dysmorphic glomeruli
[9,10]. Although Vangl2Lp/+ kidneys develop normally,
compound heterozygotes harbouring Vangl2Lp and a
point mutation in another PCP gene, Cadherin EGF
LAG seven-pass G-type receptor 1 (Celsr1), have
branching malformations [11].
PCP is also implicated in acquired kidney dis-
ease. Mitotic orientation, a PCP-mediated process,
is aberrant in kidney cystogenesis [12]. Glomerular
Vangl2 transcripts increased 48 h after the initiation
of kidney injury by nephrotoxic nephritis (NTN), a
progressive disease model, and NTN is more severe
in mice with podocyte-specific Vangl2 deletion [8].
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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However, how Vangl2 modulates glomerular injury
is unclear. Possibly, Vangl2 attenuates NTN-induced
podocyte depletion [8]. Alternatively, Vangl2 might
modulate tissue remodelling. Indeed, Vangl2 alters the
activity of matrix metalloproteinases (MMPs). Vangl2
downregulation in zebrafish causes increased MMP14
availability, with reduced extracellular matrix (ECM)
and disrupted convergent extension [13]. Vangl2Lp/+
mice also have both increased Mmp12 transcripts and
active protein levels in their lungs [14]. Moreover,
glomerular podocytes express MMP2 and MMP9
[15,16]; the latter is upregulated in NTN [17], and
experimentally downregulating MMP9 modulates
NTN [17,18].
We hypothesised that Vangl2 impacts on glomeru-
lar disease by modulating MMP. We tested this by
analysing mouse models of irreversible and reversible
glomerular injury, both accompanied by leakage of pro-
tein into the urine. Irreversible injury was examined in
NTN mice, analogous to humans with focal segmen-
tal glomerulosclerosis (FSGS). Injection of lipopolysac-
charide (LPS) in mice was used to induce reversible
glomerular injury, as occurs in humans with minimal
change disease (MCD). Our results support the conclu-
sion that Vangl2 modulates glomerular injury, in part by
acting as a brake on MMP9.
Methods
Transgenic mice
All procedures were approved by the UK Home Office.
For specific gene deletion in glomerular podocytes,
we used PodCre mice that express Cre recombinase
driven by the promoter of podocin, a gene expressed
in podocytes from the immature capillary loop stage
of glomerular development to maturity [19]. Initially,
we examined the specificity of Cre recombination by
breeding PodCre+ mice with R26R-EYFP mice, which
have a loxP-flanked STOP sequence followed by the
enhanced yellow fluorescent protein gene (EYFP)
inserted into the Gt(ROSA)26Sor locus. Subsequently,
to delete Vangl2 in podocytes, we crossed PodCre+
mice with Vangl2flox/flox mice [20], where loxP sites
flank exon 4, with PodCre+/Vangl2/flox/+ mice being
mated to generate PodCre+/Vangl2flox/flox mice and
littermate controls, Vangl2flox/flox without Cre. Primers
to detect the PodCre, Vangl2flox and excised exon 4 of
Vangl2 (Δ band) alleles are detailed in the supplemen-
tary material, Supplementary materials and methods.
Recombination of Vangl2 by Cre generates a prema-
ture stop codon that gives rise to a protein lacking
the four trans-membrane domains and the C-terminal
PDZ-binding domain required for the interaction of
Vangl2 with other proteins [21,22]. All transgenic
mouse strains were on a C57Bl/6 background for
>10 generations.
Murine models of glomerular disease
To induce accelerated NTN [23], a model of irre-
versible and progressive glomerular damage, male
PodCre+/Vangl2flox/flox and Vangl2flox/flox mice were
pre-immunised by subcutaneous injection of sheep
immunoglobulin (0.2mg) in complete Freund’s adju-
vant. This was followed by intravenous administration
of sheep anti-mouse glomerular basement membrane
(GBM) nephrotoxic globulin (200 μl) 5 days later
to induce nephritis. Glomerular injury follows, with
capillary thrombosis and crescent formation [23].
To induce transient podocyte injury, male Pod-
Cre+/Vangl2flox/flox and Vangl2flox/flox mice were injected
with 10 μg/g LPS intraperitoneally [24]. C57Bl/6
male wild-type mice were also injected with either
phosphate-buffered saline (PBS) or LPS (n= 6 in each
group) to examine glomerular levels of PCP genes.
Histological analysis
Kidneys were fixed in 4% paraformaldehyde, dehy-
drated, wax-embedded and sectioned at 5 μm. Periodic
acid Schiff (PAS) staining was used to detect basement
membranes and sclerosis. Glomerular morphology
in 12-week-old male PodCre+/Vangl2flox/flox and
Vangl2flox/flox mice was examined by two blinded
assessors and designated as normal (little PAS-positive
material and normal capillary loops) or abnormal (PAS
in >50% of the tuft). At least 30 glomeruli from four
separate mice in each genotype were evaluated. Results
for each category were expressed as a percentage of
the total glomeruli assessed. In NTN mice, thrombosis
(PAS-positive areas of occluded capillary loops) was
scored using a scale of 0–4 depending on the number of
quadrants affected within the glomerular tuft (each tuft
divided into four quadrants for scoring purposes) [23].
Fifty glomeruli were assessed per sample by a blinded
assessor, and an average score was obtained for each
kidney.
Renal function assessment, immunofluorescence
staining, Western blotting, electron microscopy,
podocyte culture and RT-qPCR
Details are provided in supplementary material, Supple-
mentary materials and methods.
Studies of human kidney tissue
We interrogated microarray data obtained from
microdissected glomeruli from two independent cohorts
of renal patients. Cohort I included patients with FSGS
(n= 10), MCD (n= 5) and living donor (LD) healthy
controls (n= 18) from the European Renal cDNA Bank
[25] (see supplementary material, Table S1) where
RNA had been hybridised to Affymetrix HG-U133 Plus
2.0 microarrays (Santa Clara, CA, USA) [26]. Cohort
II included microarray data from the public domain
[GEO database: www.ncbi.nlm.nih.gov/geo; project
GSE108109; Affymetrix Human Gene 2.1 ST arrays
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(Santa Clara, CA, USA)]. This project includes mRNA
expression data from human renal biopsies with FSGS
(n= 16), MCD (n= 5) and controls (LDs) (n= 6). A
single probe-based analysis tool, ChipInspector (Geno-
matix Software GmbH, Munich, Germany), was used
for transcript annotation, total intensity normalisation,
significance analysis of microarrays and transcript
identification based on significantly changed probes
[27]. The statistic algorithm in ChipInspector is a T-test
that creates artificial background data by randomly
permuting the array results. Each probe has a score
on the basis of its fold-change relative to the standard
deviation of repeated measurements for this probe.
Probes with scores higher than a certain threshold
are deemed significant. This threshold is the Delta
value. The permutations of the dataset are then used to
estimate the percentage of probes identified by chance
at the identical Delta. Thus, a relation of significant
probes to falsely discovered probes can be given for
each Delta threshold. This relation is the false discovery
rate (FDR), a stringency indicator. Analysis was carried
out using all default settings as recommended by the
software provider, with an FDR of 0% and a median
false positive of 0% [27].
Statistics
Datasets [mean± standard error of mean (SEM)]
were analysed using GraphPad Prism (GraphPad Soft-
ware, La Jolla, CA, USA). Differences between two
groups were analysed using an unpaired t-test. When
comparing more than two groups, differences were anal-
ysed using one-way analysis of variance (ANOVA) with
Bonferroni’s multiple comparison post hoc tests. Data
affected by two variables were analysed using two-way
ANOVAwith Bonferroni’smultiple comparison post hoc
tests unless otherwise stated. Statistical significance was
set at p≤ 0.05.
Results
Podocyte-specificVangl2 knockdown mice
Initially, we examined the specificity of Cre recombina-
tion by breeding PodCre+ mice with R26R-EYFP mice.
In the adult kidneys of PodCre+/R26R-EYFP mice
(n= 2), we observed positive EYFP expression in a
pattern typical of podocyte expression in the glomerular
tuft (see supplementary material, Figure S1A). We
subsequently bred PodCre+ mice with Vangl2flox/flox
mice. PodCre+/Vangl2flox/flox and Vangl2flox/flox litter-
mate controls both appeared healthy. DNA isolated
from the kidney cortex of newborn (postnatal day
1) PodCre+/Vangl2flox/flox mice contained both the
truncated Vangl2 allele and the intact allele (see sup-
plementary material, Figure S1B), consistent with
Cre-mediated excision in podocytes that themselves
represent only a proportion of Vangl2 expressing cells in
the kidney cortex. We undertook qRT-PCR for Vangl2
on RNA isolated from the glomeruli of 12-week-old
PodCre+/Vangl2flox/flox and Vangl2flox/flox mice using
primers designed to span part of exon 4, finding that
Vangl2 transcripts containing exon 4 were reduced to
38% in PodCre+/Vangl2flox/flox mice (p< 0.05, n= 4
each genotype) (Figure 1A). As assessed by Western
blotting using a C-terminal antibody, Vangl2 protein
was reduced to 28% in PodCre+/Vangl2flox/flox versus
Vangl2flox/flox littermates (p< 0.05, n= 4 each geno-
type) in glomerular lysates from 12-week-old mice
(Figure 1B, C). The remaining Vangl2 expression
may be due to inefficient Cre recombination. Alter-
natively, as the mature glomerular tuft also contains
endothelia and mesangial cells, Vangl2 might also
be expressed in these cells. In this regard, we found
Vangl2 transcripts in cultured mouse endothelia by PCR
(see supplementary material, Figure S1C). There was
no significant difference in glomerular transcripts of
other core PCP components (Vangl1, Celsr1, Pk1, Pk2,
Dvl1-3) or Daam1 (encoding the downstream effector
dishevelled associated activator of morphogenesis) (see
supplementary material, Figure S2).
Next, we examined glomerular morphology and func-
tion to determine whether Vangl2 is required for normal
healthy glomeruli. Gross glomerular morphology was
assessed in 12-week-old male PodCre+/Vangl2flox/flox
and Vangl2flox/flox mice using light microscopy images
of kidney sections stained with PAS (Figure 1D).
Significantly (p< 0.05) fewer normal (category a)
glomeruli were observed in PodCre+/Vangl2flox/flox
mice (58.4± 6.7%) versus Vangl2flox/flox (84.8± 3.1%).
Accordingly, the percentage of abnormal (category
b) glomeruli was significantly (p< 0.05) higher in
PodCre+/Vangl2flox/flox mice (41.6± 6.7%) compared
with Vangl2flox/flox (15.2± 2.2%) (Figure 1E). There was
no significant difference in podocyte number between
the two genotypes as assessed by quantifying the
number of WT1+ cells in at least 30 glomeruli from
each mouse (see supplementary material, Figure S3).
Glomerular ultrastructure was assessed by electron
microscopy (Figure 1F), and no significant difference
was observed in GBM or average foot process (FP)
width between PodCre+/Vangl2flox/flox and Vangl2flox/flox
mice (Figure 1G, H). To assess glomerular macromolec-
ular barrier function, we quantified albuminuria over
24 h (Figure 1I), and to examine excretion of circulating
small molecules, we measured plasma creatinine levels
(Figure 1J). No significant differences were observed
between the two genotypes for either parameter at
12weeks.
Genetic downregulation of Vangl2 in podocytes
worsens experimental nephritis
Thus, deletion of podocyte Vangl2 led to modest aber-
rations of glomerular morphology, but this did not lead
to increased albuminuria or kidney excretory failure.
Therefore, we proceeded to investigate possible roles for
Vangl2 in experimentally induced glomerular disease.
We first used a model of irreversible and progressive
glomerular damage, accelerated NTN. Here, mice are
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Figure 1. Podocyte-specific Vangl2 knockdown is associated with glomerular dysmorphology but no impairment of kidney function. (A)
Vangl2mRNA expression in glomerular isolates of Vangl2flox/flox and PodCre+/Vangl2flox/flox mice by RT-qPCR (n = 4). (B) Representative west-
ern blot of glomerular lysates isolated from adult PodCre+/Vangl2flox/flox and Vangl2flox/flox mice (n = 4 per genotype). (C) Semi-quantitative
densitometric analysis shows that Vangl2 protein in PodCre+/Vangl2flox/flox mice is reduced (p< 0.05) compared with littermate Vangl2flox/flox
controls. (D) Representative images of category (a) normal and (b) abnormal glomeruli used to assess glomerular morphology, scale
bar = 20 μm. Normal glomeruli contain numerous patent capillary loops surrounded by a thin basement membrane stained red by PAS
(arrows), whereas abnormal glomeruli have fewer patent capillary loops and increased PAS staining (arrows in b). (E) PodCre+/Vangl2flox/flox
mice had fewer normal (category a) glomeruli than Vangl2flox/flox controls and more category b glomeruli, (p< 0.05, n = 4 in each genotype,
30–50 glomeruli/sample). (F) Transmission electron micrographs of representative glomeruli from the two genotypes. Endo, endothelial
cell; pod, podocyte. Magnification=×10 500. Quantification of GBM width (G) and average FP width (H) (n = 4 in each genotype, 10
images/sample). (I) Twenty-four-hour albumin excretion in urine of Vangl2flox/flox (n = 12) and PodCre+/Vangl2flox/flox mice (n = 12) col-
lected at 12weeks. (J) Plasma creatinine concentration in Vangl2flox/flox (n= 8) and PodCre+/Vangl2flox/flox mice (n = 11) at 12weeks of age.
All values are presented as mean± SEM; ns= not significant.
pre-immunised with sheep immunoglobulin, and 5 days
later, nephritis is induced by nephrotoxic globulin (see
supplementary material, Figure S4A). Previous work
has shown that glomerular Vangl2 transcripts increased
48 h after the initiation of NTN [8].
Seven days after disease induction, nephropathic mice
displayed a range of glomerular abnormalities, includ-
ing capillary thrombosis, mesangial matrix deposition,
FSGS and glomerular epithelial hyperplasia, the latter
representing early crescent formation (Figure 2A).
We found that PodCre+/Vangl2flox/flox mice had sig-
nificantly increased glomerular thrombosis scores
compared with Vangl2flox/flox mice (2.0± 0.2 versus
1.1± 0.3, p< 0.02 (Figure 2B). There was an approxi-
mately two-fold higher prevalence of severely damaged
glomeruli (scores 2–4) in PodCre+/Vangl2flox/flox versus
Vangl2flox/flox mice (67.7± 7.1% and 36.2± 14.3%,
respectively (p< 0.05)) (Figure 2C). Following NTN,
average 24-h albumin excretion was significantly
increased in Vangl2flox/flox mice versus levels before
immunisation (p< 0.05, Figure 2D). Strikingly, in
nephropathic mice, albuminuria was an average
of 2.5-fold higher in PodCre+/Vangl2flox/flox versus
Vangl2flox/flox mice (p< 0.01, Figure 2D). Plasma creati-
nine (Figure 2E) levels in the Vangl2flox/flox mice 7 days
after NTN induction were similar to those before immu-
nisation. In nephropathic PodCre+/Vangl2flox/flox mice,
however, creatinine significantly increased versus levels
before induction of nephritis (p< 0.05). As creatinine is
a by-product of muscle metabolism, we also measured
body weight but found no significant difference between
the two nephropathic groups (see supplementary mate-
rial, Figure S4B). We measured the number of WT1+
positive cells in at least 30 glomeruli/mouse and found
that the average number of podocytes per glomerular
area was not different between PodCre+/Vangl2flox/flox
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 246: 485–496
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Figure 2. Podocyte-specific Vangl2 knockdown exacerbates glomerular sclerosis and albuminuria following NTN. (A) Representative images
of PAS-stained glomeruli used to score thrombosis, scale bar= 20 μm. Arrows show areas of thrombosis (occluded capillary lumens), and *
indicates a glomerular crescent. (B) Thrombosis score was higher, and a greater percentage of glomeruli were severely affected (C) (categories
2–4) in PodCre+/Vangl2flox/flox mice compared with controls (n = 6–11 in each group, 50 glomeruli/sample). (D) Twenty-four-hour albumin
excretion in urine and (E) plasma creatinine concentration, n= 6–11. Quantification of F4/80+ cells in the glomerular tuft (F) and
peri-glomerular area (G) of Vangl2flox/flox and PodCre+/Vangl2flox/flox mice (n = 6–11 in each group, 30 glomeruli/sample). All values are
presented as mean± SEM; ns, not significant.
and Vangl2flox/flox mice with NTN (see supplementary
material, Figure S4C, D). There was also no difference
in amounts of IgG deposited within glomeruli between
nephropathic PodCre+/Vangl2flox/flox and Vangl2flox/flox
mice 7 days after NTN induction (see supplementary
material, Figure S4E, F), indicating that the difference
in disease severity between the two groups was not due
to changes in glomerular antibody binding.
We also examined whether genetic deletion of
podocyte Vangl2 affected immune cell infiltration
because this modulates the initiation and progression
of NTN [28]. We assessed numbers of F4/80+ posi-
tive macrophages [29] in glomerular tufts (Figure 2F)
and in areas surrounding glomeruli (Figure 2G). In
glomerular tufts before injury, very few F4/80+ pos-
itive macrophages were detected in either genotype,
and there was no significant change following NTN
injury. After induction of nephritis, F4/80+ cells around
glomeruli increased in Vangl2flox/flox (p< 0.01) and Pod-
Cre+/Vangl2flox/flox kidneys, although in the latter case,
this did not reach statistical significance (p= 0.06), but
there was no difference between genotypes.
Deletion of Vangl2 in podocytes alters MMP9
during NTN
We hypothesised that genetic deletion of Vangl2
in podocytes altered MMP activity, which could
subsequently contribute to the increased disease sever-
ity of NTN observed in PodCre+/Vangl2flox/flox mice.
First, we knocked down Vangl2 using siRNA in cul-
tured mouse podocytes and measured transcript levels
of Mmp2 and Mmp9, both of which have been detected
in podocytes [16]; Mmp12, of which transcript lev-
els are increased in Vangl2 mutant lungs [14]; and
Mmp14, whose availability is elevated in zebrafish
with Vangl2 downregulation [13]. Vangl2 siRNA
resulted in a >90% knockdown in Vangl2 (Figure 3A)
and significantly increased mRNA levels of Mmp9
(p< 0.05) (Figure 3B) but did not affectMmp2,Mmp12
or Mmp14 (Figure 3C–E) levels (n= 3 from at least
three independent experiments analysed in triplicate).
Next, we examined MMP9 expression in detail. MMP9
was detected by immunohistochemistry at baseline
(see supplementary material, Figure S5). Following
NTN, in both Vangl2flox/flox and PodCre+/Vangl2flox/flox
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 246: 485–496
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Figure 3. Vangl2 siRNA knockdown increasesMmp9 mRNA levels. Podocytes grown in vitro under permissive conditions were differentiated
for 14 days before being transfected with control siRNA or siRNA targeting Vangl2. (A) Quantification of Vangl2 mRNA levels in podocytes
48 h after transfection. Relative mRNA levels ofMmp9 (B)Mmp2 (C),Mmp12 (D) andMmp14 (E). Experiments were repeated three to four
times, and results are expressed as mean± SEM. ns, not significant.
Figure 4. Podocyte-specific Vangl2 knockdown increases MMP9 activity following NTN. (A–F) Representative pictures of immunostaining
for MMP9 (A and D), nephrin (B and E) and merged images (C and F) in Vangl2flox/flox and PodCre+/Vangl2flox/flox mice (upper and lower
panel, respectively) following the administration of nephrotoxic serum. Arrowheads indicate areas of overlapping podocyte staining in both
genotypes. (G) Representative western blot for MMP9 from whole kidney lysates 7 days after NTN induction. (H) The ratio of active MMP9
to pro-MMP9 in PodCre+/Vangl2flox/flox mice is increased compared with Vangl2flox/flox controls, p< 0.02, n = 6–11 in each group. (I and
J) Representative images of collagen IV-stained glomeruli scored 0 or 1. Arrowheads show positive staining in the glomerular tuft arising
from the GBM surrounding the capillary loops. (K and L) Representative images of ZO-1 stained glomeruli scored 0 or 1. Arrowheads show
positive staining in the glomerulus. (M) Quantification of collagen IV and (N) ZO-1 staining at baseline and following NTN, expressed as
average score per glomerulus, in Vangl2flox/flox and PodCre+/Vangl2flox/flox mice (n = 6–11 in each group, 30 glomeruli/sample). All values
are presented as mean± SEM; ns, not significant.
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mice, MMP9 immunostaining partly spatially over-
lapped with nephrin, a podocyte slit diaphragm protein
(Figure 4A–F). Using Western blots, we quantified
MMP9 in whole kidneys of nephropathic Vangl2flox/flox
and PodCre+/Vangl2flox/flox mice, probing with an
antibody that detects both the inactive form (105 kDa;
pro-MMP9) and the cleaved, enzymatically active
form (95 kDa; active-MMP9) (Figure 4G). The aver-
age ratio of active MMP9 to pro-MMP9 increased
by 40% in PodCre+/Vangl2flox/flox versus Vangl2flox/flox
tissues (Figure 4H) (6.1± 0.4 to 4.4± 0.1 respectively,
p< 0.05, n= 6–11 per group).
We examined the expression of collagen IV, an
MMP9 substrate [30] and a key GBM component [31],
using immunofluorescent staining of kidney sections,
at baseline and during NTN, with an antibody reactive
to all collagen IV chains. Quantification was performed
by assigning a score of 0 to glomeruli with staining
in <50% of the tuft area and a score of 1 to glomeruli
with staining in >50% of the tuft (Figure 4I, J). There
was no significant difference between Vangl2flox/flox
and PodCre+/Vangl2flox/flox before induction of NTN.
During NTN, the collagen IV score was reduced in
both Vangl2flox/flox and PodCre+/Vangl2flox/flox mice
versus healthy controls (p< 0.01), but no difference
was observed between the two genotypes (Figure 4M).
We also quantified ZO-1, a tight junction protein [32]
degraded by MMP9 in cultured podocytes [33], by
immunofluorescent staining using the same scoring
system (Figure 4K, L). In nephropathic mice, ZO-1
immunostaining in PodCre+/Vangl2flox/flox kidneys was
reduced (p< 0.02) to approximately half the level
measured in Vangl2flox/flox organs (Figure 4N).
Podocyte Vangl2 deletion enhances LPS-induced
glomerular injury and modulates MMP9
Next, we determined whether Vangl2 plays a role
in another glomerular disease model, LPS-induced
reversible glomerular injury. Here, podocytes are
injured through the activation of the toll-like receptor
4, leading to FP effacement within 24–48 h, fol-
lowed by resolution after 72 h [24]. One day after
LPS administration, the urinary albumin/creatinine
ratio was, on average, three-fold greater (p< 0.05)
in PodCre+/Vangl2flox/flox versus Vangl2flox/flox mice
(Figure 5A). Albuminuria continued to increase in both
groups until 48 h, with a non-significant (p= 0.68)
tendency for higher values in PodCre+/Vangl2flox/flox
Figure 5. Podocyte-specific Vangl2 knockdown exacerbates albuminuria and increases MMP9 activity following LPS injury. (A) Eight to
ten-week-old mice were injured with LPS (10 μg/g), and albuminuria was measured at 24, 48 and 72 h. PodCre+/Vangl2flox/flox mice had
higher urine albumin to creatinine ratio at 24 h compared to Vangl2flox/flox controls (n = 5–6 per genotype), p< 0.05 by two-way ANOVA
and Fisher’s least square difference test. (B) RT-qPCR of core PCP genes in isolated glomeruli following injury with LPS or PBS. Representative
immunoblot of MMP 9 (active and pro) in glomerular lysates from Vangl2flox/flox and PodCre+/Vangl2flox/flox mice prior to (C) and (D) 24 h
following LPS. Densitometric analysis using ImageJ software at baseline (E) and after LPS (F) in PodCre+/Vangl2flox/flox mice compared to
Vangl2flox/flox controls (n = 5–6 per genotype). All values are presented as mean± SEM; ns, not significant.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 246: 485–496
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Table 1. Levels of PCP transcripts are altered in human glomerular disease
Cohort I Cohort II
Entrez gene ID Gene symbol
FSGS (n= 10)
versus LDs (n= 18)
MCD (n= 5)
versus LDs (n= 18)
FSGS (n= 16)
versus LDs (n= 6)
MCD (n= 5)
versus LDs (n= 6)
81839 VANGL1 1.37 1.24 1.68 ns
57216 VANGL2 1.53 ns 1.66 ns
9620 CELSR1 1.06 0.78 ns ns
1952 CELSR2 1.28 ns 2.08 ns
1855 DVL1 1.25 ns ns ns
1856 DVL2 1.24 ns 1.70 ns
1857 DVL3 1.23 ns 1.69 ns
7976 FZD3 1.27 ns ns ns
144165 PRICKLE1 1.31 1.34 1.71 ns
166336 PRICKLE2 1.30 ns 0.83 ns
Single-probe analysis for selected PCP transcripts in microdissected glomeruli from two independent cohorts of renal patients with focal and segmental
glomerulosclerosis (FSGS); MCD and living kidney donors (LD) used as controls. Values are expressed as fold-change compared to LD. Significantly upregulated genes
are shown in red and downregulated genes in blue. Transcripts with a fold-change above 1.5 or below 0.667 are displayed in bold.
mice (2052± 1129 μg/mg) versus Vangl2flox/flox ani-
mals (1465±576 μg/mg). Albuminuria returned to
basal levels by 72 h in both genotypes. We examined
transcript levels of Vangl1, Vangl2, Celsr1 and Pk1 in
isolated glomeruli 24 h after LPS injury and found no
significant differences compared with mice injected
with PBS (Figure 5B). MMP9 levels in glomerular
lysates from PodCre+/Vangl2flox/flox and Vangl2flox/flox
were assessed using Western blotting (Figure 5C, D).
In glomeruli harvested from either genotype before
administration of LPS (n= 4–6 in each group), most
MMP9 was in the inactive form (Figure 5C) with ratios
of active-MMP to pro-MMP9< 1 in both genotypes
and no statistically significant difference between the
genotypes (Figure 5E). LPS injury in Vangl2flox/flox
mice resulted in an average ratio of active/pro-MMP9
of 1.2± 0.4. Strikingly, the active/pro-MMP9 ratio in
PodCre+/Vangl2flox/flox LPS glomeruli was 4.3± 1.2,
significantly higher (p< 0.05) versus Vangl2flox/flox
tissues (Figure 5F).
Levels of PCR transcripts in human glomerular
disease
To begin to examine the human relevance of this work,
we assessed levels of transcripts encoded by PCP genes
(VANGL1, VANGL2,CELSR1,CELSR2,DISHEVELED
1-3, FRIZZLED3, PRICKLE1 and PRICKLE2) in
glomeruli from biopsies of individuals with either
FSGS or MCD from two different cohorts of patients
(Table 1). In cohort I, significant increases versus
healthy controls were observed for all PCP transcripts
examined in FSGS, including VANGL2, which was
upregulated >1.5-fold. Similar findings were observed
in cohort II, with significant increases found in 6 of
the 10 genes evaluated, one of which was VANGL2. In
contrast, in samples fromMCD patients in cohort I, only
VANGL1 and PRICKLE1 were significantly increased
versus healthy kidneys, whereas CELSR1 levels were
downregulated by 0.8-fold. There were no significant
changes in any of the PCP genes examined in the MCD
patients in cohort II.
Discussion
Targeted genetic downregulation of Vangl2 in podocytes
enhanced the severity of both accelerated NTN and
LPS-induced glomerular damage. In each proteinuric
model, genetic deletion of Vangl2 in podocytes was
associated with an increased ratio of active-MMP9 to
inactive-MMP9. These observations support the con-
clusion that Vangl2 modulates glomerular injury in
mice, at least in part by acting as a brake on MMP9,
a potentially harmful endogenous enzyme. In addi-
tion, by interrogating data from two cohorts of renal
patients, we report increased VANGL2 transcript levels
in glomeruli of individuals with FSGS, providing evi-
dence that the molecule may also be involved in certain
human glomerular diseases.
Previously, we [10] and others [9] showed that
Loop-tail (Lp) mice with homozygous point muta-
tions in Vangl2 had malformed kidneys containing
fewer ureteric tree collecting duct branches and
fewer mature glomeruli. However, the Vangl2Lp/Lp
mouse is not an ideal model to define the spe-
cific glomerular roles of Vangl2. First, the mutation
would affect Vangl2 in both nephron and collect-
ing duct lineages. Accordingly, because nephrons
including glomerular and collecting duct develop-
ment are interdependent, the glomerular phenotype
could be a secondary effect. Second, homozygous Lp
mutants die neonatally, precluding their use in testing
roles for Vangl2 in glomerular function and disease
in adulthood.
To circumvent this, we used a conditional
Vangl2flox/flox mouse [19] and deleted Vangl2 specif-
ically in glomerular podocytes. In this model, we found
that there were no alterations in other PCP compo-
nents in the kidney at the transcriptional level but
cannot rule out possible differences in their localisa-
tion. Indeed, the Lp mutation affects the localisation
of certain PCP components such as Pk2 [34], Friz-
zled 3 [21] and Vangl1 [35]. Based on our previous
observations on the Loop-tail mouse [10] and other
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evidence supporting a role for Vangl2 in podocyte
morphology [36], we initially hypothesised that a lack
of podocyte Vangl2 might result in impaired glomerular
morphology and function. We found that the kidneys
of 12-week-old PodCre+/Vangl2flox/flox did contain a
slight but statistically significant increased proportion
of morphologically abnormal glomeruli. This is likely
explained by the fact that podocin promoter-driven Cre
expression, and thus Vangl2 recombination, would start
in immature glomeruli, in the capillary loop stage. Kid-
ney function, however, appeared preserved in adults as
assessed by plasma creatinine and urinary albumin lev-
els. Our results concur with Rocque and colleagues [8],
who showed that podocyte-specific deletion of Vangl2
using the same PodCre line in our study led to smaller
glomeruli at 2weeks of age, but this also did not lead
to any changes in albuminuria. Furthermore, genetic
deletion of podocyte Scribble, encoding another PCP
core protein, did not lead to any changes in glomerular
morphology or function [37]. Collectively, these results
suggest that the knockdown of an individual PCP
component does not have a major effect on glomerular
biology of otherwise healthy mice. On the other hand,
our observations on Vangl2 and Celsr1 compound het-
erozygous mice showed a more severe foetal glomerular
defect than either mouse alone [11]. Future studies on
mice lacking multiple PCP components could provide
more insights into the potential role of this pathway in
glomerular morphogenesis.
A key finding in our study is that glomerular
injury, induced by nephrotoxic serum or LPS, is
aggravated in mice with genetic downregulation of
podocyte Vangl2 compared with controls. Although
there was no difference in albumin excretion between
PodCre+/Vangl2flox/flox and Vangl2flox/flox mice before
glomerular injury, we cannot rule out that the increased
proportion of morphologically abnormal glomeruli seen
in PodCre+/Vangl2flox/flox mice makes these animals
more susceptible to injury. In future, inducing NTN
in mice in which Vangl2 is deleted in adulthood by
an inducible PodCre allele [38] should help unravel
whether the above modest glomerular maturation defect
is playing a confounding role in worsening the severity
of nephritis in mice with podocyte-specific Vangl2
depletion.
How might Vangl2 downregulation lead to enhanced
kidney injury? Possible mechanisms include cytoskele-
tal rearrangements affecting cell morphology [39] or
changes in inflammation [14]. However, in this study,
we focused on the effect of Vangl2 downregulation
on MMPs, which modulate tissue remodelling. First,
we examined which MMPs were altered in cultured
podocytes following Vangl2 downregulation and found
increased transcript levels of Mmp9. Furthermore, in
both injury models, Vangl2mutants had increased ratios
of active-MMP9 to inactive MMP9. MMP9 has previ-
ously been shown to be produced by podocytes [16,33]
and altered in a number of glomerular diseases, includ-
ing lupus nephritis with active, fibrocellular crescents
[40], DN [33,41]; viral-associated glomerulonephritis
[42], membranous [43] and hypertensive [44] nephropa-
thy. MMP9 is also induced by activation of the toll-like
receptor 4 [45,46], which mediates the actions of LPS.
The exact mechanism of how PCP proteins regulate
MMPs is not fully understood. One possibility is through
the regulation of vesicular trafficking [13]. Alterna-
tively, Vangl2 can regulate cell surface integrin αvβ3
expression and adhesion to fibronectin, laminin and
vitronectin [47].
We subsequently examined some of the mechanisms
through which increased MMP activity might aggra-
vate glomerular disease in NTN. MMPs were originally
characterised by their ability to break down ECM [48];
therefore, we examined collagen IV, a key component
of the glomerular ECM [31]. However, we did not find
any difference in collagen IV expression between Pod-
Cre+/Vangl2flox/flox and Vangl2flox/flox animals with NTN.
Recent studies using proteomic approaches have shown
that the glomerular ECM is composed of over 140
structural and regulatory components [49], and future
experiments could examine the detailed ECM proteome
of nephropathic PodCre+/Vangl2flox/flox and Vangl2flox/flox
animals. LPS injury in mice also results in remodelling
of the GBM 24 h later. A glomerular microarray study
found elevated levels of transcripts encoding collagen IV
α1 and α2 chains alongside laminin α5β2γ1 [50], both
of which normally predominate in immature glomeruli
[51]; we postulate that MMP9 may play a role in this
process.
In vitro, podocyte exposure to exogenous MMP9 was
shown to degrade ZO-1, a tight junction protein [32].
We also examined the distribution of ZO-1 in vivo fol-
lowing NTN and found a significant reduction in Pod-
Cre+/Vangl2flox/flox mice. Ultrastructure assessment of
mice kidneys with NTN has shown that tight junc-
tion formation is an early abnormality in NTN, pre-
ceding FP effacement and podocyte bridge formation
[52]. The authors postulated that podocyte-to-podocyte
tight junction function may be a compensatory mecha-
nism to maintain glomerular filtration barrier integrity.
Therefore, the loss of ZO-1 in PodCre+/Vangl2flox/flox
mice with NTN may lead to filtration barrier disrup-
tion and account for the enhanced albuminuria seen in
these mice. MMP9 has also been shown to upregulate
podocyte integrin-linked kinase (ILK) secretion [33],
a kinase known to induce podocyte de-differentiation
and detachment in disease conditions [53]; whether it is
upregulated in the setting of dysfunctional PCP remains
to be elucidated. Further studies inhibiting MMPs in
PCP-deficient mice would help to delineate their role in
this pathway. Chemical inhibition of MMP activity has
already been shown to be beneficial in some models of
glomerular damage [54,55], and based on our observa-
tions, we would predict a similar role in dysfunctional
PCP-associated glomerular damage.
To begin to examine the relevance of our mouse
studies to human disease, we examined PCP transcripts
in microdissected glomeruli from FSGS and MCD
patients. In data from two independent cohorts of FSGS
patients, significant increases versus LDs were observed
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for the majority of PCP transcripts examined. Impor-
tantly, in both FSGS cohorts, VANGL2 was upregulated
>1.5-fold, suggesting this molecule may have an impor-
tant biological role in FSGS. It should be noted that there
were some discordant results between the two cohorts
analysed (e.g. in the number of PCP transcripts found to
be significantly altered), and follow-up studies should
confirm the microarray data by RT-qPCR and assess
VANGL2 at the protein level in human glomeruli. In
accord with the human data, a significant upregulation
of Dvl2, Fz3, Pk1 and Vangl2 glomerular transcripts
was detected in NTN mice 48 h after the induction
of disease [8]. Interestingly, changes in glomerular
ECM deposition are a feature of FSGS and NTN
[56,57], whereas in MCD or LPS glomerular disease,
where there is no sclerosis or excess ECM deposition,
the majority of PCP genes examined were unaltered.
Collectively, the finding of VANGL2 upregulation in
FSGS, coupled with the observation that glomerular
disease is worsened in mice deficient for Vangl2 in
podocytes, suggests that increased PCP gene expres-
sion in glomerular disease is likely to be a protective
compensatory response.
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